bluuebunny/crossref_metadata_2025_split huggingface dataset:
Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids
Authors: Sorrin Aaron , Dasgupta Anika , McNaughton Kathryn , Arnau Del Valle Carla , Zhou Keri , Liu Cindy , Roque Dana M. , Huang Huang Chiao 
Published: February 2024

Abstract
Background
Within the last decade, poly(ADP-ribose) polymerase inhibitors (PARPi) have emerged in the clinic as an effective treatment for numerous malignancies. Preclinical data have demonstrated powerful combination effects of PARPi paired with photodynamic therapy (PDT), which involves light-activation of specialized dyes (photosensitizers) to stimulate cancer cell death through reactive oxygen species generation.

Results
In this report, the most potent clinical PARP inhibitor, talazoparib, is loaded into the core of a polymeric nanoparticle (NP-Tal), which is interfaced with antibody-photosensitizer conjugates (photoimmunoconjugates, PICs) to form PIC-NP-Tal. In parallel, a new 3D fluorescent coculture model is developed using the parental OVCAR-8-DsRed2 and the chemo-resistant subline, NCI/ADR-RES-EGFP. This model enables quantification of trends in the evolutionary dynamics of acquired chemoresistance in response to various treatment regimes. Results reveal that at a low dosage (0.01 μM), NP-Tal kills the parental cells while sparing the chemo-resistant subline, thereby driving chemoresistance. Next, PIC-NP-Tal and relevant controls are evaluated in the 3D coculture model at multiple irradiation doses to characterize effects on total spheroid ablation and relative changes in parental and subline cell population dynamics. Total spheroid ablation data shows potent combination effects when PIC and NP-Tal are co-administered, but decreased efficacy with the conjugated formulation (PIC-NP-Tal). Analysis of cell population dynamics reveals that PIC, BPD + NP-Tal, PIC + NP-Tal, and PIC-NP-Tal demonstrate selection pressures towards chemoresistance.

Conclusions
This study provides key insights into manufacturing parameters for PARPi-loaded nanoparticles, as well as the potential role of PDT-based combination therapies in the context of acquired drug resistance.
Protocol for spatial prediction of soil transmitted helminth prevalence in the Western Pacific region using a meta-analytical approach
Authors: Gilmour Beth , Wangdi Kingley , Restrepo Angela Cadavid , Tsheten Tsheten , Kelly Matthew , Clements Archie , Gray Darren , Lau Colleen , Espino Fe Esperanza , Daga Chona , Mapalo Vanessa , Vaz Nery Susana , Bartlett Adam , Gebreyohannes Eyob Alemayehu , Alene Kefyalew Addis 
Published: February 2024

Abstract
Background
Soil transmitted helminth (STH) infections are estimated to impact 24% of the world’s population and are responsible for chronic and debilitating morbidity. Disadvantaged communities are among the worst affected and are further marginalized as infection prevalence fuels the poverty cycle. Ambitious targets have been set to eliminate STH infections, but accurate epidemiological data will be required to inform appropriate interventions. This paper details the protocol for an analysis that aims to produce spatial prediction mapping of STH prevalence in the Western Pacific Region (WPR).

Methods
The protocol follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol (PRISMA-P) guidelines. The study design will combine the principles of systematic review, meta-analysis, and geospatial analysis. Systematic searches will be undertaken in PubMed, Scopus, ProQuest, Embase, and Web of Science for studies undertaken post 2000, to identify surveys that enable the prevalence of human STH infection within the WPR to be calculated. Covariate data for multivariable analysis will be obtained from publicly accessible sources. Survey data will be geolocated, and STH prevalence and covariates will be linked to produce a spatially referenced dataset for analysis. Bayesian model-based geostatistics will be used to generate spatially continuous estimates of STH prevalence mapped to a resolution of 1 km2. A separate geospatial model will be constructed for each STH species. Predictions of prevalence will be made for unsampled locations and maps will be overlaid for each STH species to obtain co-endemicity maps.

Discussion
This protocol facilitates study replication and may be applied to other infectious diseases or alternate geographies. Results of the subsequent analysis will identify geographies with high STH prevalence’s and can be used to inform resource allocation in combating this neglected tropical disease.

Trial registration
Open Science Framework: osf.io/qmxcj.
Association of serum 25-hydroxyvitamin D concentrations with all-cause and cardiovascular mortality among US adults with prehypertension: a prospective cohort study
Authors: Zhou Yongmei , Chen Yu , Chen Fuli , Li Gang , Zhou Long 
Published: February 2024

Abstract
Background
Prehypertension affects 25–50% of adults worldwide and no prior study has examined the relationship between serum 25-hydroxyvitamin D [25(OH)D] concentrations and mortality risk in individuals with prehypertension. This study aims to investigate the association of serum 25(OH)D concentrations with all-cause and CVD mortality among prehypertensive adults by utilizing data from the US National Health and Nutrition Examination Survey (NHANES) 2007–2014 and linked 2019 mortality file.

Methods
We included 4345 prehypertensive adults who participated in the NHANES between 2007 and 2014 and were followed up until 31 December 2019. Weighted Cox proportional hazards models were used with adjustments for multiple covariates to calculate the hazard ratio (HR) and 95% confidence interval (CI) for the risks of dying from any cause and CVD.

Results
During a median follow-up of 8.8 years, 335 deaths from any causes were documented, of which 88 participants died from CVD. Compared with participants with sufficient 25(OH)D (≥ 75 nmol/L), the multivariate-adjusted HRs and 95% CIs for participants with severe deficiency (< 25 nmol/L), moderate deficiency (25–49.9 nmol/L), and insufficient concentrations (50–74.9 nmol/L) of serum 25(OH)D for all-cause death were 2.83 (1.46–5.52), 1.17 (0.74–1.86), and 1.36 (0.93–1.98), respectively. Similarly, the multivariable-adjusted HRs and 95%CIs for CVD death were 4.14 (1.10–15.51), 1.23 (0.46–3.28), and 1.73 (0.96–3.14), respectively. We found that there was a 9% reduction in the risk of death from all causes and a 14% reduction in the risk of death from CVD for every 10 nmol/L increase in serum 25(OH)D concentrations.

Conclusion
Severe serum 25(OH)D deficiency among prehypertensive adults was associated with increased risk of mortality from all causes as well as from CVD. Our work suggests that supplementing with vitamin D may prevent premature death in severely deficient individuals with prehypertension.
Industry 5.0 and SDG 9: a symbiotic dance towards sustainable transformation
Authors: Costa Evaldo 
Published: February 2024

AbstractThe convergence of Industry 5.0 (I5.0) and Sustainable Development Goal 9 (SDG 9) signifies a transformative shift in global industries, propelled by a new triple bottom line approach– human-centric, sustainable, and resilient. Departing from traditional models, I5.0, an evolution from Industry 4.0, strategically aligns with SDG 9 to reshape industrial landscapes and promote global sustainable, resilient, and inclusive development.I5.0’s emphasis on resource optimization and collaboration between humans and machines marks a departure from technologically driven manufacturing (I4.0), ushering in a sustainable production model. Cutting-edge technologies, including Artificial Intelligence (AI), Machine Learning (ML), and automation, optimize resource utilization, enhancing operational efficiency to support sustainability goals. Yet, challenges like initial implementation costs and a lack of global sustainability standards pose obstacles.The human-centric integration within I5.0 prioritizes human needs throughout the manufacturing process. Collaborations with Cobots and AI-ML technologies optimize workflows, contribute to customization, and align with SDG 9’s vision, necessitating robust training programs and strategic considerations for workforce adaptation and financial investments.Exploring I5.0 resilience within SDG 9 unveils its pivotal role during crises, such as the COVID-19 pandemic. Discussions navigate challenges related to supply chain disruptions, economic impacts, and geopolitical factors, emphasizing the need for strategic resilience, sustainability, and human-centric approaches. I5.0 resilience, guided by Cobots, aligns with SDG 9’s focus on resilient infrastructure.Sustainable Business Model Innovation (SBMI) emerges as a central point of contention in the I5.0 and SDG 9 interplay. Advocates tout its transformative potential for sustainability goals, while skeptics question scalability and adaptability, reflecting the complexity of factors in achieving sustainable and resilient industrial development.Therefore, the strategic imperative of I5.0 and SDG 9 unfolds as a transformative force for positive change, embedded in SBMI. This collaborative journey transcends the confines of a production system, ushering in a future where technology management, supported by SBMI, proactively reinforces resilience, societal well-being, and environmental stewardship. The future of I5.0 raises questions about innovative ecosystems, collaboration practices, geopolitical impacts, circular production models, and extending I5.0 beyond current geographical limits.
An artificial intelligence approach of feature engineering and ensemble methods depicts the rumen microbiome contribution to feed efficiency in dairy cows
Authors: Monteiro Hugo F. , Figueiredo Caio C. , Mion Bruna , Santos José Eduardo P. , Bisinotto Rafael S. , Peñagaricano Francisco , Ribeiro Eduardo S. , Marinho Mariana N. , Zimpel Roney , da Silva Ana Carolina , Oyebade Adeoye , Lobo Richard R. , Coelho Jr Wilson M. , Peixoto Phillip M. G. , Ugarte Marin Maria B. , Umaña-Sedó Sebastian G. , Rojas Tomás D. G. , Elvir-Hernandez Modesto , Schenkel Flávio S. , Weimer Bart C. , Brown C. Titus , Kebreab Ermias , Lima Fábio S. 
Published: February 2024

AbstractGenetic selection has remarkably helped U.S. dairy farms to decrease their carbon footprint by more than doubling milk production per cow over time. Despite the environmental and economic benefits of improved feed and milk production efficiency, there is a critical need to explore phenotypical variance for feed utilization to advance the long-term sustainability of dairy farms. Feed is a major expense in dairy operations, and their enteric fermentation is a major source of greenhouse gases in agriculture. The challenges to expanding the phenotypic database, especially for feed efficiency predictions, and the lack of understanding of its drivers limit its utilization. Herein, we leveraged an artificial intelligence approach with feature engineering and ensemble methods to explore the predictive power of the rumen microbiome for feed and milk production efficiency traits, as rumen microbes play a central role in physiological responses in dairy cows. The novel ensemble method allowed to further identify key microbes linked to the efficiency measures. We used a population of 454 genotyped Holstein cows in the U.S. and Canada with individually measured feed and milk production efficiency phenotypes. The study underscored that the rumen microbiome is a major driver of residual feed intake (RFI), the most robust feed efficiency measure evaluated in the study, accounting for 36% of its variation. Further analyses showed that several alpha-diversity metrics were lower in more feed-efficient cows. For RFI,[Ruminococcus] gauvreauii groupwas the only genus positively associated with an improved feed efficiency status while seven other taxa were associated with inefficiency. The study also highlights that the rumen microbiome is pivotal for the unexplained variance in milk fat and protein production efficiency. Estimation of the carbon footprint of these cows shows that selection for better RFI could reduce up to 5 kg of diet consumed per cow daily, potentially reducing up to 37.5% of CH4. These findings shed light that the integration of artificial intelligence approaches, microbiology, and ruminant nutrition can be a path to further advance our understanding of the rumen microbiome on nutrient requirements and lactation performance of dairy cows to support the long-term sustainability of the dairy community.
Effect of manila palm (
Veitchia merrillii
Becc.) on rumen fermentation and microbial population in beef heifers
Authors: Pongjongmit Tanitpan , Norrapoke Thitima , Phesatcha Kampanat 
Published: February 2024

Abstract

The aim of the study was to evaluate the influence of manila palm (MP) on rumen fermentation and rumen microbial ecology in beef cattle. Four Brahman crossbred heifers with an initial body weight (BW) of 250 ± 40 kg (1–1.5 years old) were randomly assigned according to a 4 × 4 Latin square design to the following treatments: (1) Control (0% concentrate powder MP), (2) 1% concentrate powder MP, (3) 3% concentrate powder MP, and (4) 5% concentrate powder MP. The manila palm contained 12.54% of condense tannin. Cow were fed with a rice straw ad libitum and concentrate at 1%BW. There were no treatments effect on ruminal pH, NH
3
-N, microbial protein synthesis, nor ruminal temperature. Inclusion of MP did not affect (P > 0.12) blood urea N and hematocrit. However, ruminal concentration of acetic acid was linearly decreased (P < 0.01), while propionic acid was linearly increased (P < 0.01) as MP was increased in diet. In a such a manner that predicted ruminal CH
4
production was decreased (P < 0.01) as MP was increased in diet. Inclusion of MP in diet decreased linearly (P = 0.02) protozoal population as MP level increased. The present study suggests that manila powder has modulatory effects on ruminal fermentation, decreasing acetate to propionate ratio, reducing estimated CH
4
production without effects on ruminal pH, microbial synthesis nor blood parameters. Changes on ruminal fermentation parameters could be partially explained by decreases in the ruminal protozoa. Supplementation beyond 3% of concentrate portion (approximately 1.2% of total ration DM intake) did not increase significantly this positive effects, thus is recommended 1.2% of total ration as optimal use as an animal feed supplement.
Assessment of seizure duration and utility of using SedLine® EEG tracing in veterans undergoing electroconvulsive therapy: a retrospective analysis
Authors: Amirfarzan Houman , Cassidy Kaitlin Jane , Moaddab Mehrak , Demin Ma , Schumann Roman , Lewis Bradford 
Published: February 2024

Abstract
Background
Electroconvulsive therapy (ECT) endures as a definitive treatment for refractory depression and catatonia and is also considered an effective treatment for a number of other severe psychiatric disorders (Lisanby, N Engl J Med 357:1939-1945, 2007)(Weiner and Prudic, Biol Psychiatry 73:105-106, 2013). GA is an essential component of the ECT procedure for various reasons (Lee, Jenkins and Sparkle, Life 11, 2021). Monitoring anesthetic effects on the brain is desirable as anesthetic agents affect seizure duration and recovery (Rasulo, Hopkins, Lobo, et al, Neurocrit Care 38:296-311, 2023) (Jones , Nittur , Fleming and Applegate, BMC Anesthesiol 21:105, 2021) (Soehle , Kayser , Ellerkmann and Schlaepfer, BJA 112:695-702, 2013). Perioperative anesthetic effects on consciousness can be assessed with brain function monitoring using raw electroencephalogram (EEG) traces and processed EEG indices.

Objective
We examined the usefulness and utility of the SedLine® anesthetic effect monitor during ECT procedures. We hypothesized that the seizure duration as measured by the EEG tracing of the ECT machine is equivalent to the duration assessed by the SedLine® EEG tracing. A secondary objective was to describe the SedLine® patient state indices (PSI) at different phases of treatment.

Methods
Following IRB approval, we analyzed the data of the electronic medical records of 45 ECT treatments of 23 patients in an urban VA medical center between July 01, 2021, and March 30, 2022. We compared the seizure duration in minutes and seconds as measured either by the ECT machine EEG tracing or the SedLine® EEG tracing. We then collected SedLine® processed EEG indices at four different stages during the treatment. Appropriate comparative and observational statistical analyses were applied.

Results
There was no significant difference in measured seizure duration between the two methods examined (p < 0.05). We observed a lag of the SedLine PSI value at the time before stimulus delivery and limited PSI utility during the course of ECT.

Conclusion
The SedLine® EEG tracing can be an alternative to the machine EEG tracing for the determination of seizure duration. The SedLine® processed EEG indices are not consistently useful before and after ECT delivery. Anesthetic effect monitoring during ECT is feasible.
Functional Status Associations With Treatment Receipt and Outcomes Among Older Adults Newly Diagnosed With Multiple Myeloma
Authors: Jensen Christopher Edward , Kuo Tzy-Mey , LeBlanc Matthew R. , Baggett Christopher D. , Duchesneau Emilie D. , Zhou Xi , Reeder-Hayes Katherine E. , Lund Jennifer L. 
Published: February 2024

PURPOSE Multiple myeloma (MM) is a prevalent hematologic malignancy in older adults, who often experience physical disability, increased health care usage, and reduced treatment tolerance. Home health (HH) services are frequently used by this group, but the relationship between disability, HH use, and MM treatment receipt is unclear. This study examines the connections between disability, treatment receipt, and survival outcomes in older adults with newly diagnosed MM using a nationwide data set. METHODS The SEER-Medicare data set was used to identify adults aged 66 years and older diagnosed with MM from 2010 to 2017, who used HH services the year before diagnosis. Disability was assessed with the Outcome and Assessment Information Set, using a composite score derived from items related to ability to complete activities of daily living. Mortality, therapy receipt, and health care utilization patterns were evaluated. RESULTS Of 37,280 older adults with MM, 6,850 (18.2%) used HH services before diagnosis. Moderate disability at HH assessment resulted in similar MM-directed therapy receipt as mild disability, with comparable health care usage after diagnosis to severe disability. HH users had a higher comorbidity burden and higher mortality (adjusted risk ratio for 3-year mortality: 1.59 [95% CI, 1.55 to 1.64]). Severe functional disability before diagnosis was strongly related to postdiagnosis mortality. CONCLUSION Among older adults with MM receiving HH services, disability is a predictor of early mortality. Moderately disabled individuals undergo similar therapy intensity as the mildly disabled but experience increased acute care utilization. Previous HH use could identify patients with MM requiring intensive support during therapy initiation.
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
Authors: Mateos Maria-Victoria , Robak Pawel , Hus Marek , Xia Zhongjun , Zherebtsova Vera , Ward Christopher , Ho P. Joy , Hajek Roman , Kim Kihyun , Dimopoulos Meletios A. , Cerchione Claudio , Riccio Antonio , McKeown Astrid , Rogers Rachel , Baig Hena , Eccersley Lydia , Roy-Ghanta Sumita , Opalinska Joanna , Hungria Vania 
Published: February 2024

439572 Background: Belamaf, a BCMA-targeted antibody drug conjugate, has previously demonstrated clinical activity and a manageable safety profile, supporting its use in combination with standard-of-care (SoC) therapies in RRMM. DREAMM-7 (NCT04246047) is a global, randomized, open-label, phase III head-to-head trial evaluating the efficacy and safety of BVd triplet vs SoC triplet, DVd, in patients (pts) with RRMM with ≥1 prior line of therapy (LOT). Methods: Pts with ≥1 prior LOT were randomized (1:1) to BVd: B 2.5 mg/kg IV Q3W + V 1.3 mg/m2 (D1, 4, 8, 11 of 21-day cycles (C); up to 8 C) + d 20 mg (D1, 2, 4, 5, 8, 9, 11, 12; up to 8 C) or DVd: D 16 mg/kg (21-day C), C1-3, Q1W, C4-8, Q3W, and Q4W from C 9 on); V and d schedules were the same. The primary endpoint was independent review committee-assessed progression free survival (PFS). Secondary endpoints available include overall survival (OS), duration of response (DOR), overall response rate (ORR). Results: 494 pts were randomized (BVd n = 243, DVd n = 251). With a median (range) follow-up of 28.2 mo (0.10-40 mo), the median PFS (mPFS) in the BVd arm was 36.6 mo (95% CI, 28.4 mo-NR) vs 13.4 mo (11.1-17.5 mo) with DVd; hazard ratio (HR) 0.41 (95% CI, 0.31-0.53; p < 0.00001). OS data was 29% mature; median OS was not reached in either arm; HR, 0.57 (95% CI, 0.40-0.80; nominal p < 0.0005). ORR was 82.7% (95% CI, 77.4-87.3%) with BVd and 71.3% (65.3-76.8%) with DVd. Median DOR (mDOR) was 35.6 mo (95% CI, 30.5 mo-NR) for BVd vs 17.8 mo (13.8-23.6 mo) for DVd. All pts in both arms experienced ≥1 AE (Table). Grade 3/4 treatment-related AEs (TRAE) were reported in 90% of pts in the BVd arm and 67% with DVd. Serious AEs (SAE) were reported in 50% of pts in BVd vs 37% in DVd arm. Ocular AEs were more frequent on BVd vs DVd (79% vs 29%) and were manageable. Conclusions: The DREAMM-7 head-to-head study of BVd vs DVd demonstrated statistically significant PFS benefit of BVd with a mPFS improvement of 23 mo in pts with RRMM with ≥1 prior LOT. A strong and clinically meaningful OS benefit (nominal p < 0.0005) was observed. Additionally, BVd led to greater depth of response and doubling of mDOR vs DVd and had a manageable safety profile. These results support BVd as a potential new SoC in this setting. Clinical trial information: NCT04246047 . [Table: see text]
Association of Major Adverse Financial Events and Later-Stage Cancer Diagnosis in the United States
Authors: Warren Joan L. , Mariotto Angela B. , Stevens Jennifer , Davidoff Amy J. , Shankaran Veena , Ward Kevin C. , Wu Xiao-Cheng , Schwartz Stephen M. , Penberthy Lynne , Yabroff K. Robin 
Published: February 2024

PURPOSE This study assessed the prevalence of specific major adverse financial events (AFEs)—bankruptcies, liens, and evictions—before a cancer diagnosis and their association with later-stage cancer at diagnosis. METHODS Patients age 20-69 years diagnosed with cancer during 2014-2015 were identified from the Seattle, Louisiana, and Georgia SEER population–based cancer registries. Registry data were linked with LexisNexis consumer data to identify patients with a history of court-documented AFEs before cancer diagnosis. The association of AFEs and later-stage cancer diagnoses (stages III/IV) was assessed using separate sex-specific multivariable logistic regression. RESULTS Among 101,649 patients with cancer linked to LexisNexis data, 36,791 (36.2%) had a major AFE reported before diagnosis. The mean and median timing of the AFE closest to diagnosis were 93 and 77 months, respectively. AFEs were most common among non-Hispanic Black, unmarried, and low-income patients. Individuals with previous AFEs were more likely to be diagnosed with later-stage cancer than individuals with no AFE (males—odds ratio [OR], 1.09 [95% CI, 1.03 to 1.14]; P < .001; females—OR, 1.18 [95% CI, 1.13 to 1.24]; P < .0001) after adjusting for age, race, marital status, income, registry, and cancer type. Associations between AFEs prediagnosis and later-stage disease did not vary by AFE timing. CONCLUSION One third of newly diagnosed patients with cancer had a major AFE before their diagnosis. Patients with AFEs were more likely to have later-stage diagnosis, even accounting for traditional measures of socioeconomic status that influence the stage at diagnosis. The prevalence of prediagnosis AFEs underscores financial vulnerability of patients with cancer before their diagnosis, before any subsequent financial burden associated with cancer treatment.